Catalent
   HOME

TheInfoList



OR:

Catalent, Inc. (Catalent Pharma Solutions) is a multinational corporation headquartered in
Somerset, New Jersey Somerset is an unincorporated community and census-designated place (CDP) located within Franklin Township, in Somerset County, New Jersey, United States.biologics A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, th ...
, gene therapies and consumer health products. It employs more than 14,000 people, including approximately 2,400 scientists and technicians. In fiscal year 2020, it generated over $3 billion in annual revenue. Catalent was formed in April 2007 when affiliates of the Blackstone Group L.P. acquired the core of the pharmaceutical technologies and services (PTS) segment of
Cardinal Health, Inc Cardinal or The Cardinal may refer to: Animals * Cardinal (bird) or Cardinalidae, a family of North and South American birds **''Cardinalis'', genus of cardinal in the family Cardinalidae **'' Cardinalis cardinalis'', or northern cardinal, th ...
. Cardinal Health created PTS through a series of acquisitions starting with R.P. Scherer Corporation in 1998. In 2014, Catalent became a
public company A public company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (l ...
and is listed on the
New York Stock Exchange The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed c ...
.


History


Before 2007

In 1996,
Cardinal Health Cardinal Health, Inc. is an American multinational health care services company, and the 14th highest revenue generating company in the United States. Its headquarters are in Dublin, Ohio and Dublin, Ireland (EMEA). The company specializes in th ...
acquired PCI (Headquarters:
Philadelphia, Pennsylvania Philadelphia, often called Philly, is the largest city in the Commonwealth of Pennsylvania, the sixth-largest city in the U.S., the second-largest city in both the Northeast megalopolis and Mid-Atlantic regions after New York City. Sinc ...
). PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging. In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters:
Troy, Michigan Troy is a city in Oakland County, Michigan, United States. Its population was 87,294 at the 2020 U.S. census, making Troy the most populous city in the county and the 13th most-populous municipality in the state. Troy is a northern suburb of Me ...
).
Robert Pauli Scherer Robert Pauli Scherer (1906–1960) was an American inventor who founded the RP Sherer Corporation. In 1933, Scherer invented the rotary die encapsulation process, revolutionizing the soft-gelatin encapsulation field. He founded the R. P. Sch ...
founded the R.P. Scherer Corporation to commercialize his innovation of
softgel A softgel is an oral dosage form for medicine in the form of a specialized capsule. They consist of a gelatin based shell surrounding a liquid fill. Softgel shells are a combination of gelatin, water, opacifier and a plasticiser such as glycerin ...
encapsulation using the rotary die production process. The following year, in 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.), whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market. In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise. In 2003, Cardinal Health acquired Gala Biotech (Headquarters:
Madison, Wisconsin Madison is the county seat of Dane County and the capital city of the U.S. state of Wisconsin. As of the 2020 census the population was 269,840, making it the second-largest city in Wisconsin by population, after Milwaukee, and the 80th-lar ...
). In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe. From 2004 to 2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple acquisitions.


Formation of Catalent in 2007

In 2007, the pharmaceutical technologies and services segment of Cardinal Health was purchased by Blackstone Group and re-branded as ''Catalent Pharma Solutions''.


After 2007 and initial public offering-2019

In 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore. Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany. In 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co, a China-based company, and Relthy Laboratories in Brazil. Catalent announced its
initial public offering An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail (individual) investors. An IPO is typically underwritten by one or more investment ...
in July 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE). The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on 31 July 2014, under the ticker symbol CTLT. In November 2014, Catalent announced it had acquired Micron Technologies, a provider of particle size engineering technologies. The acquisition allowed Catalent to expand its portfolio of drug delivery technologies. In 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with
oncology Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an ''oncologist''. The name's etymological origin is the Greek word ὄγκος (''ó ...
development, and bought Pharmatek Laboratories to add spray drying to their manufacturing capabilities. In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, allowing Catalent to expand their biologic manufacturing. In July 2018, Catalent extended their work with Juniper Pharmaceuticals with a $133 million deal. Alessandro Maselli was appointed as president and chief operating officer in 2019, a newly created position within Catalent. In March, 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new
Zydis Zydis is a technology used to manufacture orally disintegrating tablets developed by R.P. Scherer Corporation. Zydis tablets dissolve in the mouth within 3 seconds. History Zydis technology was developed by R.P. Scherer Corporation (currentl ...
lines; changes to one of their facilities in
Swindon Swindon () is a town and unitary authority with Borough status in the United Kingdom, borough status in Wiltshire, England. As of the 2021 Census, the population of Swindon was 201,669, making it the largest town in the county. The Swindon un ...
, UK; and a custom suite for commercial equipment. Later in 2019, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method. In April 2019, Catalent agreed to acquire Paragon Bioservices Inc for $1.2 billion to expand its gene-therapy manufacturing capabilities. The deal was completed in May 2019 and included an agreement with Sarepta Therapeutics, a gene therapy manufacturer. As of October 2019, Paragon's employee numbers have almost doubled since the April acquisition. In June 2019, Catalent acquired Bristol-Myers' European launch pad to expand its global CDMO.


2020-Present

In January 2020, Catalent purchased a manufacturing facility located in
Anagni Anagni () is an ancient town and ''comune'' in the province of Frosinone, Lazio, Latium, central Italy, in the hills east-southeast of Rome. It is a historical and artistic center of the Latin Valley. Geography Overview Anagni still maintains the ...
, Italy, from
Bristol-Myers Squibb The Bristol Myers Squibb Company (BMS) is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the world's largest pharmaceutical companies and consistently ranks on the ''Fortune'' 500 list of the lar ...
, to manufacture and package biologic and oral solid dose products for multiple companies. In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million. The acquisition allows Catalent to expand into cell therapy development. In 2020, Catalent partnered with multiple drugmakers, including
Pfizer Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...
,
Johnson & Johnson Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company i ...
,
AstraZeneca AstraZeneca plc () is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas includin ...
, and
Moderna Moderna, Inc. ( ) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to produ ...
to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccine candidates. In the partnership with AstraZeneca, Catalent will provide manufacturing from its Maryland facility and vial filling and packaging from its Italian facility. Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's
St. Petersburg Saint Petersburg ( rus, links=no, Санкт-Петербург, a=Ru-Sankt Peterburg Leningrad Petrograd Piter.ogg, r=Sankt-Peterburg, p=ˈsankt pʲɪtʲɪrˈburk), formerly known as Petrograd (1914–1924) and later Leningrad (1924–1991), i ...
facility. Also in 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics. In August 2021, Catalent announced plans to acquire nutritional supplement company Bettera Holdings LLC for $1 billion. The deal will allow Catalent to manufacture vitamins, minerals and supplements in gummy form. In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in
Shiga, Japan is a prefecture of Japan located in the Kansai region of Honshu. Shiga Prefecture has a population of 1,412,916 (1 October 2015) and has a geographic area of . Shiga Prefecture borders Fukui Prefecture to the north, Gifu Prefecture to the northe ...
. In October 2022, Catalent announced a $12M expansion at a
Kansas City, MO Kansas City (abbreviated KC or KCMO) is the largest city in Missouri by population and area. As of the 2020 census, the city had a population of 508,090 in 2020, making it the 36th most-populous city in the United States. It is the central ...
facility. January 2023, Catalent partnered with
Sarepta Sarepta (near modern Sarafand, Lebanon) was a Phoenician city on the Mediterranean coast between Sidon and Tyre, also known biblically as Zarephath. It became a bishopric, which faded, and remains a double (Latin and Maronite) Catholic titular ...
to manufacture delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced
gene therapy Gene therapy is a medical field which focuses on the genetic modification of cells to produce a therapeutic effect or the treatment of disease by repairing or reconstructing defective genetic material. The first attempt at modifying human DN ...
candidate for the treatment of
Duchenne muscular dystrophy Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy that primarily affects boys. Muscle weakness usually begins around the age of four, and worsens quickly. Muscle loss typically occurs first in the thighs and pelvis fol ...
(DMD).


Financials


References


External links

* {{Authority control Companies based in Somerset County, New Jersey Pharmaceutical companies established in 2007 Companies listed on the New York Stock Exchange Pharmaceutical companies based in New Jersey Gene therapy Biotechnology companies of the United States Multinational companies headquartered in the United States Life sciences industry Drug discovery companies Research and development in the United States 2014 initial public offerings